	US 12,018,078 B2
	SEMA4D antibody, preparation method therefor and use thereof
Yingying Hu, Shanghai (CN); Xiaodan Cao, Shanghai (CN); Zihan Jin, Shanghai (CN); Lina Wang, Shanghai (CN); Yuandong Wang, Shanghai (CN); Xiaohui Shao, Shanghai (CN); Shaoping Hu, Shanghai (CN); Mingming Pan, Shanghai (CN); Yan Liu, Shanghai (CN); Wei Shao, Shanghai (CN); Yanyan Li, Shanghai (CN); Xiaoxuan Lan, Shanghai (CN); Ying Gu, Shanghai (CN); Siran Zhu, Shanghai (CN); Lile Liu, Shanghai (CN); and Qing Duan, Shanghai (CN)
Assigned to JIANGSU HUAIYU PHARMACEUTICAL CO., LTD., Jiangsu (CN)
Appl. No. 17/260,022
Filed by JIANGSU HUAIYU PHARMACEUTICAL CO., LTD., Jiangsu (CN)
PCT Filed Jul. 15, 2019, PCT No. PCT/CN2019/096050 § 371(c)(1), (2) Date Feb. 16, 2021, PCT Pub. No. WO2020/011275, PCT Pub. Date Jan. 16, 2020.
Claims priority of application No. 201810768301.7 (CN), filed on Jul. 13, 2018.
Prior Publication US 2022/0073608 A1, Mar. 10, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

9 Claims

1. An antibody, which binds to SEMA4D, wherein the antibody comprises: (1) heavy chain variable region comprising the following three complementary determining regions of CDRs: VH-CDR1 comprising SEQ ID NO: 322, VH-CDR2 comprising SEQ ID NO: 323, and VH-CDR3 comprising SEQ ID NO: 324; and (2) a light chain variable region comprising the following three complementary determining regions of CDRs: VL-CDR1 comprising SEQ ID NO: 326, VL-CDR2 comprising SEQ ID NO: 327, and VL-CDR3 comprising SEQ ID NO: 328.